OPK Investee NVCN Q3 CC

Neovasc Reports Results for the Third Quarter of 2015

NASDAQ: NVCN
TSX: NVC
VANCOUVER, Nov. 9, 2015 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced financial results for the quarter ended September 30, 2015.
"Of critical importance during the quarter we continued to advance our Tiara transcatheter mitral valve program, making adjustments to our clinical program to increase enrolment and completing development of the 40mm size," commented Neovasc CEO, Alexei Marko. "Development of the 45mm size is underway in addition to other improvements that will broaden the applicable patient population. Neovasc's Tiara technology remains at the forefront of products under development for transcatheter mitral valve replacement.  We are advancing the Tiara program in a careful and controlled manner in order to most effectively bring Tiara to market to meet this pressing need."
"For the second quarter in a row, Reducer's sales in Europe have met our expectations and in particular, the reorder rate from our early adopters is an encouraging sign for this device's longer-term acceptance into standard medical practice," said Chris Clark, CFO of Neovasc.  "Reducer's performance is important to our business plan, as we continue to transition our focus from our legacy tissue business lines to our internally developed medical device products. Our cash position remains very strong with ample funds to support our clinical and regulatory programs for Tiara and Reducer in the near term."
Tiara Update
To date, eleven patients have been implanted with Tiara in early feasibility and compassionate use cases and early results have been encouraging. Eight of the eleven cases have proceeded substantially as intended resulting in stable implants, good prosthetic valve function, and no valvular leaks. In two of the eleven cases Tiara was malpositioned during implant, which required conversion to surgery, with one Tiara being explanted, the other repositioned and fully functional.  In the remaining case, the patient developed a ventricular septal defect caused by the Tiara device, which the Company believes should be avoided in the future through modifications it has made to the screening process.  To date, the 30-day survival rate for the first eleven patients implanted with Tiara is 73% with one patient now over 600 days post implant.  Tiara devices have been successfully implanted in both functional and degenerative MR patients, as well as patients with pre-existing prosthetic aortic valves and mitral surgical rings, using both 35mm and 40mm Tiara devices.   Additional details of implantation results will be presented at appropriate medical conferences as they become available.
The results from these early feasibility and compassionate use cases have been instrumental in helping to demonstrate the potential of the Tiara as well as refining the implantation procedure, patient selection criteria and the device itself.  The Company is continuing to expand its clinical program and the 45mm Tiara is in development.
Revenues
Revenue for the three months ended September 30, 2015, were $3,237,810 compared to revenues of $4,269,360 for the same period in 2014. Revenues for the nine months ended September 30, 2015, were $9,698,290 compared to revenues of $12,510,010 for the same period in 2014. The Company is refocusing its business away from its traditional revenue towards development and commercialization of its own products, the Reducer and Tiara.
The Company ceased its production of surgical patches (product sales) in June 2015. The Company started its sales of Reducer in the first quarter of 2015 as it initiated its focused commercialization of the product in Europe. 
Reducer sales for the three months ended September 30, 2015 were $208,631, compared to $nil for the same period in 2014. Reducer sales for the nine months ended September 30, 2015 were $424,299, compared to $nil for the same period in 2014. Included within these revenues are stocking orders from new territories and re-orders from certain territories in Europe.  The success of the commercialization of Reducer will be dependent on the amount of internal resources allocated to the product, obtaining appropriate reimbursement codes in various territories and correctly managing the referrals process.
Cost of Goods Sold
The cost of goods sold for the three and nine months ended September 30, 2015 was $2,058,989 and $6,286,597, respectively, compared to $2,468,747 and $7,450,193 for the same periods in 2014.  The overall gross margin for the three and nine months ended September 30, 2015 was 36% and 35%, respectively, compared to 42% and 40% gross margin for the same periods in 2014. We lost a significant higher margin contract manufacturing account toward the end of 2014 and have seen during the year our consulting services revenue margins decline as our ability to charge higher fees for these services has decreased as the transcatheter aortic valve market has matured.
Expenses
Total expenses for the three and nine months ended September 30, 2015 were $12,533,549 and $29,598,438, respectively, compared to $6,423,477 and $16,555,555 for the same periods in 2014, representing an increase of $6,110,072 or 95%, and $13,042,883 or 79%, respectively. The increase in total expenses for the three months ended September 30, 2015 compared to the same period in 2014 reflects a $129,816 increase in selling expenses as we commercialize Reducer, a $3,043,239 increase in general and administrative expenses (of which $3,306,231 relates to an increase in litigation expenses) and a $2,937,017 increase in product development and clinical trial expenses to advance the Tiara and Reducer development programs. The increase in total expenses for the nine months ended September 30, 2015 compared to the same period in 2014 reflects a $393,473 increase in selling expenses as we commercialize Reducer, a $4,536,884 increase in general and administrative expenses (of which $6,086,957 relates to an increase in litigation expenses) and a $8,112,526 increase in product development and clinical trial expenses to advance the Tiara and Reducer development programs.
Selling expenses for the three and nine months ended September 30, 2015 were $149,101 and $457,086, respectively, compared to $19,285 and $63,613 for the same periods in 2014, representing an increase of $129,816, or 673%, and $393,473 or 619%. The increase in selling expenses for the three and nine months ended September 30, 2015 compared to the same periods in 2014 reflects costs incurred for Reducer commercialization activities in the first nine months of 2015. The Company anticipates a significant increase in selling expenses in 2015 and 2016 as it initiates a focused commercialization of the Reducer in select countries in Europe.
General and administrative expenses for the three and nine months ended September 30, 2015 were $5,959,380 and $13,193,866, respectively, compared to $2,916,141 and $8,656,982 for the same periods in 2014, representing an increase of $3,043,239, or 104% and $4,536,884, or 52%, respectively.  The increase in general and administrative expenses for the three months ended September 30, 2015 compared to the same period in 2014 can be substantially explained by a $3,306,231 increase in litigation expenses, a $355,087 increase in cash based employee expenses and offset by a $750,604 decrease in share-based payments.  The increase in general and administrative expenses for the nine months ended September 30, 2015 compared to the same period in 2014 can be substantially explained by a $6,086,957 increase in litigation expenses, a $727,979 increase in cash based employee expenses and offset by a $2,526,241 decrease in share-based payments. In 2015 the Company adjusted its compensation plan to directors, officers and senior management, decreasing the number of options granted by 75%, replacing these options with a smaller cash based bonus plan and increasing officers and senior management's base salaries by 10%; other cash based employee expenses are related to additional headcount in quality, finance and HR departments and with other employee expenses.
Product development and clinical trial expenses for the three and nine months ended September 30, 2015 were $6,425,068 and $15,947,486, respectively, compared to $3,488,051 and $7,834,960 for the same periods in 2014, representing an increase of $2,937,017, or 84% and $8,112,526, or 104%.  The increase in product development and clinical trial expenses for the three months ended September 30, 2015 was due to a $829,470 increase in cash–based employee expenses as the Company hired additional staff to advance product development, a $2,616,845 increase in other expenses as the Company invested in its two major new product initiatives, offset by a $509,298 decrease in share-based payments. The increase in product development and clinical trial expenses for the nine months ended September 30, 2015 was due to a $2,301,124 increase in cash–based employee expenses as the Company hired additional staff to advance product development, a $6,006,599 increase in other expenses as the Company invested in its two major new product initiatives, offset by a $195,197 decrease in share-based payments.
The Company's expenses are subject to inflation and cost increases.  Salaries and wages have increased on average by 6% in the nine months ended September 30, 2015 compared to the same period in 2014.  The Company has not seen a material increase in the price of any of the components used in the manufacture of its products and services.
Other Income
The other income for the three and nine months ended September 30, 2015 was $1,363,668 and $1,734,426, respectively, compared to $34,319 and $55,210 for the same periods in 2014. The Company's investments in high interest savings accounts and guaranteed investment certificates generated $212,254 and $644,744 interest during the three and nine months ended September 30, 2015. The Company benefited from significant foreign exchange gains on its foreign currency-denominated cash and cash equivalents and accounts receivable during the three and nine months ended September 30 2015 of $1,165,265 and $1,146,442 respectively.
Losses
The losses for the three and nine months ended September 30, 2015 were $9,991,060 and $24,452,319, or $0.15 and $0.38 basic and diluted loss per share, as compared with a loss of $4,588,545 and $11,440,528, or $0.09 and $0.22 basic and diluted loss per share for the same periods in 2014.  The $5,402,515 increase in the loss incurred for the three months ended September 30, 2015 compared to the same period in 2014 can be substantially explained by a $621,792 decrease in gross profit, a $3,043,239 increase in general and administrative expenses (of which $3,306,231 relates to an increase in litigation expenses), $2,937,017 increase in product development and clinical trial expenses, and offset by a $1,329,349 increase in other income. The $13,011,791 increase in the loss incurred for the nine months ended September 30, 2015 compared to the same period in 2014 can be substantially explained by a $1,648,124 decrease in gross profit, a $4,536,884 increase in general and administrative expenses (of which $6,086,957 relates to an increase in litigation expenses), a $8,112,526 increase in product development and clinical trial expenses, and offset by $1,679,216 increase in other income.  Litigation expenses for the three and nine months ended September 30, 2015 represent a loss of $0.05 and $0.09 basic and diluted loss per share compared to a loss of $0.01 and $0.01 basic and diluted loss per share for the same periods in 2014. Total litigation costs since the initial claims were filed in June 2014 are approximately $7.4 million and we may require an additional $5.2 million to cover additional litigation expenses up until the trial, scheduled for May 2016.
Discussion of Liquidity and Capital Resources
Neovasc finances its operations and capital expenditures with cash generated from operations, lines of credit, and equity financings.  At September 30, 2015, the Company had cash and cash equivalents of $84,099,496 compared to cash and cash equivalents of $6,025,013 at December 31, 2014.
Cash used in operating activities for the three and nine months ended September 30, 2015, was $9,038,591 and $19,681,487, respectively, compared to $3,693,697 and $5,855,902 for the same periods in 2014.  For the three months ended September 30, 2015, operating expenses were $8,866,700, compared to $2,150,205 for the same period in 2014, cash expenditures on litigation (litigation expenses less change in accounts payable related to litigation) were approximately $3.3 million and cash expenditures on research and development and clinical trials (expenses less share based payments and depreciation) were approximately $5.6 million. Working capital items absorbed cash of $531,396, compared to $1,597,452 for the same period in 2014, as accounts receivable absorbed less cash associated with the revenue decrease, inventory absorbed cash for the preparation of future sales, prepaid expenses and other assets generated cash due to decreased prepayment of purchasing, and accounts payable provided cash due to significant litigation expenses incurred but not paid for at September 30, 2015. For the nine months ended September 30, 2015, operating expenses were $20,598,076, compared to $4,678,840 for the same period in 2014, cash expenditures on litigation (litigation expenses less change in accounts payable related to litigation) were approximately $5.5 million and cash expenditures on research and development and clinical trials (expenses less share based payments and depreciation) were approximately $13.5 million. Working capital items generated cash of $286,879, compared to working capital items absorbed cash of $1,267,195 for the same period in 2014, due to significant litigation expenses incurred but not paid for at September 30, 2015.
Outstanding Share Data
As at November 9, 2015, the Company had 66,567,597 common voting shares issued and outstanding.  Further, the following securities are convertible into common shares of the Company: 7,988,483 stock options with a weighted average price of $3.83.  The fully diluted share capital of the Company at November 9, 2015 is 74,556,080.
The Company prepares its consolidated financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board.
Neovasc's 2015 Third Quarter Financial Statements and Notes and its Management's Discussion and Analysis (MD&A) will be posted on the Company's website at www.neovasc.com and will be filed on SEDAR and EDGAR. In addition to the summary contained herein, readers are encouraged to review the full disclosure in Neovasc's Financial Statements for the three months ending September 30, 2015 and Management's Discussion and Analysis.
Conference Call and Webcast Information
Neovasc will be hosting a conference call today at 8 am ET to discuss its third quarter results.  To participate in the conference, dial 888 390 0549 or 416 764 8682.  A recording of the call will be available for 72 hours by calling 888 390 0541 or 416 764 8677 and using passcode 878085#.  A link to the live and archived audio webcast of the conference call will also be available on the Presentations and Events page of the Investors section of Neovasc's website at www.neovasc.com.
NEOVASC INC.

Condensed Interim Consolidated Statements of Financial Position (Unaudited)

(Expressed in Canadian dollars)





















September 30,
2015





December 31,
2014













(Audited)

ASSETS















Current assets

















Cash and cash equivalents



$

84,099,496



$

6,025,013





Investments





-





11,999,999





Accounts receivable





2,124,767





1,790,971





Inventory





818,292





475,975





Prepaid expenses and other assets





275,052





259,261



Total current assets





87,317,607





20,551,219

















Non-current assets

















Property, plant and equipment





4,826,032





3,078,041



Total non-current assets





4,826,032





3,078,041















Total assets



$

92,143,639



$

23,629,260















LIABILITIES AND EQUITY















Liabilities















Current liabilities

















Accounts payable and accrued liabilities



$

3,479,781



$

2,513,072





Current portion of long-term debt





-





44,591



Total current liabilities





3,479,781





2,557,663

















Non-current liabilities

















Long-term debt





-





157,628



Total non-current liabilities





-





157,628

















Total liabilities





3,479,781





2,715,291

















Equity

















Share capital





188,656,937





99,169,635





Contributed surplus





21,614,341





18,899,435





Deficit





(121,607,420)





(97,155,101)



Total equity





88,663,858





20,913,969















Total liabilities and equity



$

92,143,639



$

23,629,260


 
NEOVASC INC.

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited)

For the three and nine months ended September 30,

(Expressed in Canadian dollars)















Three months ended
September 30,



Nine months ended
September 30,





2015



2014



2015



2014



















REVENUE

















Reducer

$

208,631

$

-

$

424,299

$

-

Product sales



13,387



471,468



438,360



1,965,387

Contract manufacturing



965,099



1,366,552



2,860,112



2,273,493

Consulting services



2,050,693



2,431,340



5,975,519



8,271,130





3,237,810



4,269,360



9,698,290



12,510,010



















COST OF GOODS SOLD



2,058,989



2,468,747



6,286,597



7,450,193

GROSS PROFIT



1,178,821



1,800,613



3,411,693



5,059,817



















EXPENSES

















Selling expenses



149,101



19,285



457,086



63,613

General and administrative expenses



5,959,380



2,916,141



13,193,866



8,656,982

Product development and clinical trials expenses



6,425,068



3,488,051



15,947,486



7,834,960





12,533,549



6,423,477



29,598,438



16,555,555



















OPERATING LOSS



(11,354,728)



(4,622,864)



(26,186,745)



(11,495,738)



















OTHER INCOME/(EXPENSE)

















Interest income



198,403



77,897



590,944



153,835

Interest expense



-



(1,883)



(2,960)



(5,895)

Loss on disposal of property, plant and equipment



-



(32,022)



-



(32,022)

Gain/(loss) on foreign exchange



1,165,265



(9,673)



1,146,442



(60,708)





1,363,668



34,319



1,734,426



55,210



















LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD

$

(9,991,060)

$

(4,588,545)

$

(24,452,319)

$

(11,440,528)



















LOSS PER SHARE

















Basic and diluted loss per share

$

(0.15)

$

(0.09)

$

(0.38)

$

(0.22)
























 
NEOVASC INC.

Condensed Interim Consolidated Statements of Cash Flows (Unaudited)

For the three and nine months ended September 30,

(Expressed in Canadian dollars)















Three months ended
September 30,



Nine months ended
September 30,





2015



2014



2015



2014



















OPERATING ACTIVITIES

















Loss for the year

$

(9,991,060)

$

(4,588,545)

$

(24,452,319)

$

(11,440,528)

Adjustments for:



















Depreciation



174,289



96,638



426,664



261,271



Share-based payments



1,148,474



2,385,694



4,015,563



6,616,335



Loss on disposal of property and equipment



-



32,022



-



32,022



Interest income



(198,403)



(77,897)



(590,944)



(153,835)



Interest expense



-



1,883



2,960



5,895





(8,866,700)



(2,150,205)



(20,598,076)



(4,678,840)



















Net change in non-cash working capital items:



















Accounts receivable



(559,466)



(885,334)



(321,722)



(900,948)



Inventory



(316,313)



91,780



(342,317)



(258,449)



Prepaid expenses and other assets



211,810



(92,772)



(15,791)



(208,185)



Accounts payable and accrued liabilities



132,573



(594,826)



966,709



100,387



Customer deposits



-



(116,300)



-



-





(531,396)



(1,597,452)



286,879



(1,267,195)



















Interest paid and received:



















Interest received



345,654



55,843



578,870



96,028



Interest paid



-



(1,883)



(2,960)



(5,895)





345,654



53,960



575,910



90,133























(9,052,442)



(3,693,697)



(19,735,287)



(5,855,902)



















INVESTING ACTIVITES



















Decrease/(increase) in investments



8,097,717



(2,000,000)



11,999,999



(11,999,999)



Purchase of property, plant and equipment



(611,927)



(284,854)



(2,174,655)



(601,857)





7,485,790



(2,284,854)



9,825,344



(12,601,856)



















FINANCING ACTIVITIES



















Repayment of long-term debt



-



(10,401)



(202,219)



(30,959)



Proceeds from share issue pursuant to an underwritten
public offering, net of share issue costs of $6,236,783




-



 
-




87,083,471



 
24,645,349



Proceeds from exercise of options



11,234



24,606



1,103,174



163,384





11,234



14,205



87,984,426



24,777,774



















NET CHANGE IN CASH AND CASH EQUIVALENTS



(1,555,418)



(5,964,346)



78,074,483



6,320,016



















CASH AND CASH EQUIVALENTS

















Beginning of the period



85,654,914



15,687,834



6,025,013



3,403,472

End of the period

$

84,099,496

$

9,723,488

$

84,099,496

$

9,723,488



















Represented by:

















Cash

$

17,331,464

$

628,990

$

17,331,464

$

628,990

Cashable high interest savings accounts



34,768,032



9,094,498



34,768,032



9,094,498

Cashable guaranteed investment certificates



32,000,000



-



32,000,000



-



$

84,099,496

$

9,723,488

$

84,099,496

$

9,723,488


 
About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current fact, including statements regarding our plans to develop and commercialize products and the timing of those development programs, sources of revenues and anticipated revenues and our estimates regarding our capital requirements and future revenues, expenses and profitability and including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward looking statements are based on material assumptions  and involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such material assumptions and factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; the potential benefits of the Neovasc Reducer™ and Tiara™; the Company's receipt of any required local and institutional approvals, European enrollment and the success of applications in Europe; our anticipated use of proceeds from any financings, a history of losses and lack of and uncertainty of revenues, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. No assurances can be given as to future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.
SOURCE Neovasc Inc.



Source: PR Newswire (Nov 9, 2015 06:00:00 EST)

News by QuoteMedia
www.quotemedia.com